Peritoneal Dialysis Patents: Top Companies & Filing Trends 2026
- 60.1% concentration. The top 5 assignees hold 718 of the 1,194 records in scope — filing here means confronting a small, entrenched group first.
- Filings down 77% since the 2021 peak. From 99 records in 2021 to 23 in 2024, the complete-year data shows sustained pullback in new filing activity, not just a post-2017 plateau.
- Device claims dominate, therapy claims trail. A61M device coverage sits at 71.2% of records versus 20.7% for A61P therapeutic-activity claims — a wide gap between hardware and formulation-outcome protection.
Filing growth compares 2021 (99 records) with 2024 (23) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,194 records in scope (CR5), not by the ranked leaders only.
What this dataset covers
This landscape covers 1,194 patent records published between 2015 and mid-2026 that combine peritoneal dialysis solution or cycler claims with specific technical hooks: glucose degradation products, icodextrin formulation, membrane transport rate, peritonitis risk, automated exchange, or catheter connection. The scope is deliberately narrow — it is not general dialysis, it is the intersection of solution chemistry and cycler hardware with these named clinical and engineering concerns.
Filing activity peaked in 2017 at 110 records and has declined since, with the most recent complete year (2024) sitting well below that peak. Publication typically lags filing by around 18 months, so 2025 and 2026 figures are still filling in and should not be read as a continued decline on their own.
Filing trends and technology composition
The dataset breaks down by year, by IPC subclass and by receiving office, giving three independent views of where activity concentrates.
A sharp pullback from the 2017 peak
Filings ran from 110 in 2017 down to single digits by 2026 (partial year). The complete-year comparison of 99 records in 2021 against 23 in 2024 is a 77% drop over three years — a real and specific contraction, not an artefact of publication lag.
Device claims outweigh formulation and therapy claims
A61M (devices for body fluids) appears in 71.2% of the 1,194 records, far ahead of A61K medicinal preparations at 38.3% and A61P therapeutic activity at 20.7%. Smaller but present classes — A61J containers, B01D separation processes, A61L sterilising, C23C coating, C12Q enzyme/DNA measurement — mark narrower technical niches worth checking individually before assuming they are open.
Shares are the percentage of the 1,194 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Peritoneal Dialysis Solutions and Cyclers with Eureka
This page is one run against one query. Ask Eureka your own question about peritoneal dialysis solutions and cyclers and every answer comes back with the patent numbers behind it.
Try EurekaA representative solution-chemistry claim
Peritoneal dialysis solution
Provided is a sterilized peritoneal dialysis solution which includes an acidic first solution containing icodextrin and a second solution containing 300 to 3,000 mg/L of L-histidine and a pH controlling agent, in which the first solution contains no pH controlling agent, a pH of the first solution after sterilization is 4.0 to 5.3, a pH of the second solution after sterilization is 6.5 to 8.0, and a pH after mixing the first solution and the second solution after sterilization is 6.5 to 7.5.Filed by Terumo, published 2020-04-02. A two-compartment icodextrin formulation defined by pH ranges before and after mixing, rather than by concentration alone.
View full record in Eureka| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20100114012A1 | Portable Peritoneal Dialysis System | 212 |
| 2 | US20140018727A1 | Peritoneal dialysis systems, devices, and methods | 208 |
| 3 | US20090275883A1 | Smart patient transfer set for peritoneal dialysis | 171 |
| 4 | US20100224492A1 | Hemodialysis and peritoneal dialysis systems having electrodeionization capabilities | 153 |
| 5 | US20130041241A1 | Pecvd coating methods for capped syringes, cartridges and other articles | 152 |
| 6 | US20150005699A1 | Peritoneal dialysis systems, devices, and methods | 143 |
| 7 | US20190316948A1 | Medical treatment system and methods using a plurality of fluid lines | 125 |
| 8 | WO2013141896A1 | Peritoneal dialysis systems, devices, and methods | 107 |
| 9 | US20090275881A1 | Optimizing therapy outcomes for peritoneal dialysis | 98 |
| 10 | US20040034324A1 | User-friendly catheter connection adapters for optimized connection to multiple lumen catheters | 98 |
Citation counts reflect influence within the searched corpus and favour older filings; they are not a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers imply for filing strategy
Three figures matter most for anyone deciding where to file or challenge in this space: concentration at the top, the direction of recent filing, and where citation weight sits.
A small group controls the majority of the field
Five assignees combined account for 718 of the 1,194 records in scope, and the top 10 extend that to 999 records, or 83.7% of the field. A new entrant is filing into a space where freedom-to-operate analysis against a handful of portfolios matters more than a broad landscape scan.
Filing volume has contracted sharply since 2021
Complete-year data shows 99 records in 2021 falling to 23 in 2024. That is a real contraction in new filing, not a lag artefact, since both years are past the 18-month publication window. Whether this reflects claim-space saturation or a shift to trade-secret practice cannot be read from filing counts alone.
Older device patents still anchor prior-art searches
The most-cited records date to the 2009-2014 filing window and concern portable systems, smart transfer sets and electrodeionization-capable hemodialysis/PD hybrids. High citation counts here reflect age and searched-corpus visibility more than current relevance, but they remain the starting point for any invalidity or design-around search.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to peritoneal dialysis solutions and cyclers, with the prior art for and against each one.
Who holds the portfolios, and where the gaps sit
Filing is concentrated among a small number of legacy dialysis and materials companies, with co-assignee activity clustering around corporate restructuring rather than joint R&D.
One filer sits well ahead of the field
The leading assignee holds 249 records against 75 for the fifth-place holder and 45 for tenth place — a steep drop-off that marks this as a leader-plus-long-tail structure rather than an evenly split field.
Co-assignee pairs trace corporate lineage, not collaboration
The strongest co-assignee link, at 255 shared records, sits between two entities under the same corporate parent, and the next-strongest pairs involve the same group's successor and affiliate entities. This pattern reads as portfolio consolidation and renaming rather than joint filing between independent companies.
Momentum has flattened even among the leaders
Several of the largest historical filers show zero filings in the latest year, with year-over-year change at -100% for some. Read alongside publication lag, this signals either a genuine slowdown in new claims from incumbents or filings still working through the pipeline.
| Assignee | Recent year | YoY |
|---|---|---|
| SiO2 Medical Products | 1 | 0% |
| Baxter International Inc. | 0 | -100% |
| Baxter Healthcare SA | 0 | -100% |
| Fresenius Medical Care Holdings Inc. | 0 | — |
| NxStage Medical Inc. | 0 | -100% |
| Medtronic Inc. | 0 | — |
| Fresenius Medical Care Deutschland GmbH | 0 | — |
| Gambro Lundia AB | 0 | -100% |
Where to take this analysis
The figures here identify where the field is concentrated and where filing has slowed; turning that into a filing or challenge decision needs claim-level review.
Run a freedom-to-operate check against the top holders
With 83.7% of records held by ten assignees, a targeted FTO search against those portfolios will cover most of the relevant prior art before a broader scan is needed.
Start an FTO search in EurekaPressure-test the under-claimed branches
Thin coverage in peritonitis-risk assays and automated exchange logic does not mean the space is clear — it means it needs a closer claim-by-claim read before committing R&D spend.
Explore white space in EurekaTrack the post-2024 filing pipeline
Because 2025-2026 records are still publishing, revisit filing-trend conclusions once those years mature rather than treating the current dip as final.
Set up monitoring in EurekaCommon questions on this landscape
Filing in this space is concentrated, with the top five assignees together holding 718 of the 1,194 records in scope, or 60.1% of the field. The leading single assignee holds 249 records, well ahead of the fifth-place holder at 75. This is a leader-plus-long-tail structure: a handful of legacy dialysis and materials companies hold the bulk of the claim space, while the remaining ranked assignees each hold comparatively small counts.
Filing peaked in 2017 at 110 records and has declined since. Comparing the two most recent complete years, 2021 had 99 records and 2024 had 23, a 77% drop. Because publication lags filing by roughly 18 months, the 2025 and 2026 figures are still incomplete and should not yet be read as confirming a further decline, but the 2021-to-2024 contraction itself is based on complete-year data and is real.
The search combines peritoneal dialysis solution or cycler claims with specific technical elements: glucose degradation products, icodextrin, membrane transport rate, peritonitis risk, automated exchange and catheter connection. In IPC terms, device claims (A61M) dominate at 71.2% of records, followed by medicinal preparation claims (A61K) at 38.3% and therapeutic activity claims (A61P) at 20.7%, with smaller pockets in containers, separation processes, sterilising methods, coatings and enzyme-based measurement.
US20200101213A1, filed by Terumo and published 2020-04-02, claims a two-compartment sterilized peritoneal dialysis solution: an acidic first solution containing icodextrin with no pH controlling agent, and a second solution containing 300 to 3,000 mg/L of L-histidine plus a pH controlling agent, defined by specific pH ranges before and after mixing. Anyone formulating an icodextrin-based PD solution with a similar two-compartment pH-shift design should review this claim closely, since it is defined by pH ranges rather than by concentration ranges alone, which broadens what it can block.
Relative to the dominant device and formulation classes, coverage looks thinner in peritonitis-risk biomarker assays, automated exchange sequencing logic, catheter connection sterility interlocks, and glucose degradation product suppression chemistry. Thin coverage is a starting signal, not a guarantee of freedom to operate — each branch needs a claim-by-claim search against the top-holding assignees before committing to a filing strategy there.
Research Peritoneal Dialysis Solutions and Cyclers in depth with Eureka
Go past this page: query the whole peritoneal dialysis solutions and cyclers corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.